PéptidosRD.COM

Single Peptides · Exact presentation

GHRP-2 · 10 mg Vial

GHRP-2 · 10 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.

Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.

GHRP-2 (10 mg Vial) Dosage Protocol

The source chart summarizes “100 mcg–300 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Dosing & Reconstitution Guide

For a 10 mg presentation, the reference concentration of 3.33 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 3.33 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0333 mg at this concentration.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

The source chart summarizes “100 mcg–300 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2100 mcg (0.1 mg)3 units (0.03 mL)
Weeks 3–4150 mcg (0.15 mg)4.5 units (0.045 mL)
Weeks 5–8200 mcg (0.2 mg)6 units (0.06 mL)
Weeks 9–12 (optional)250–300 mcg (0.25–0.3 mg)7.5–9 units (0.075–0.09 mL)

Reconstitution Steps

For a 10 mg presentation, the reference concentration of 3.33 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 3.33 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0333 mg at this concentration.

Advanced / Aggressive Approach (Multiple Daily Dosing)

The source chart summarizes “100 mcg–300 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Advanced / Aggressive Approach (Multiple Daily Dosing)

PhasePer‑Injection Dose (mcg)FrequencyUnits (per injection) (mL)
Phase 1 (Weeks 1–2)100 mcg (0.1 mg)2× daily3 units (0.03 mL)
Phase 2 (Weeks 3–4)150 mcg (0.15 mg)2× daily4.5 units (0.045 mL)
Phase 3 (Weeks 5–8)200 mcg (0.2 mg)2–3× daily6 units (0.06 mL)

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]

Allow vials to reach room temperature before opening to reduce condensation uptake.

How This Works

It relates to the growth-hormone-releasing hormone, secretagogue receptor, and GH/IGF-1 axis. Each molecule acts at a different point and should not be treated as interchangeable.

Potential Benefits & Side Effects

GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.

Potential Benefits

Evidence ranges from medicines authorized for limited indications to experimental secretagogues with sparse human data. Evidence for the ingredient, formulation, and use must be separated.

Source trail

Scientific references and source discovery

How PeptidosRD selects, separates, and reviews sources